An interventional study of AGV implantation in Glaucoma, sponsored by Shahid Beheshti University of Medical Sciences. Completed. Per ClinicalTrials.gov, last updated 2008-10-17.
Sponsored by Shahid Beheshti University of Medical Sciences · Not applicable, Interventional, and Treatment
Purpose:To compare the efficacy and safety of Ahmed Glaucoma Valve (AGV) implantation in the superior versus inferior quadrants.
Methods: In a non-randomized clinical trial and over a period of two years, consecutive patients with refractory glaucoma underwent AGV implantation in the superior or inferior quadrants. Main outcome measures included best corrected visual acuity (BCVA), intraocular pressure (IOP), number of glaucoma medications, complications and success rate (defined as at least 30% IOP reduction below preoperative values and 5\<IOP\<22 mmHg with or without glaucoma medications). Other criteria for failure included implant removal, additional glaucoma surgery, phthisis bulbi or loss of light perception.
1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.
This study's enrollment of 106 is above the median of 65 across 1,272 interventional studies indexed under Glaucoma.
Browse Glaucoma studies →Shahid Beheshti University of Medical Sciences is the lead sponsor of 221 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
patients with refractory glaucoma who were candidate for AGV implantation allocated in superior site
Procedure: AGV implantation
patients with refractory glaucoma who were candidate for AGV implantation allocated in inferior site
Procedure: AGV implantation
No study locations are listed for this record.
This study is completed, as verified in Feb 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shahid Beheshti University of Medical Sciences